Skip to main content
. 2022 May 31;17(5):e0269224. doi: 10.1371/journal.pone.0269224

Table 3. Adverse events.

Adverse events Citicoline arm (n = 49) Placebo arm (n = 50) P-value
LRTI 6.1 (3/49) 10 (5/50) 0.573
Hemorrhagic transformation of infarct/ sICH 6.1 (3/49) 6 (3/50) 0.879
UTI 4.1 (2/49) 6 (3/50) 0.752
Hypotension 0 0